GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Celcuity CELC · USD

Health Care · US listing · 🇺🇸 United States

Compare

70.37

+5.36%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$154,000

FY2016FY2025

Net income

−$177.0m

FY2016FY2025

Free cash flow

−$153.5m

FY2016FY2025

Shareholders' equity

$100.6m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$154,000—————————
Gross profit−$167,000−$129,947−$142,772−$210,918−$303,235−$385,591−$338,996−$223,037−$104,704−$73,059
Research and development$145.0m$104.2m$60.6m$35.3m$25.8m$7.7m$6.3m$6.3m$5.0m$3.1m
Operating income−$172.2m−$113.3m−$66.2m−$39.4m−$28.4m−$9.6m−$7.8m−$7.9m−$6.0m−$3.3m
Net income−$177.0m−$111.8m−$63.8m−$40.4m−$29.6m−$9.5m−$7.4m−$7.5m−$6.3m−$3.3m
Diluted earnings per share-3.37-2.61-2.21-2.39-1.99-0.92-0.72-0.74-0.62-0.49

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$466.6m$245.1m$191.2m$175.7m$85.9m$13.0m$20.3m$26.0m$32.0m$6.1m
Cash and short-term investments$441.5m$235.1m$180.6m$168.6m$84.3m$11.7m$18.8m$24.9m$24.2m$5.9m
Total liabilities$366.0m$129.5m$51.5m$41.9m$17.2m$1.3m$983,229$682,210$578,053$445,359
Debt$321.9m$97.7m$37.0m$35.0m$14.6m—————
Shareholders' equity$100.6m$115.6m$139.8m$133.8m$68.7m$11.7m$19.3m$25.3m$31.4m$5.6m
Shares outstanding53m43m29m17m15m10m10m10m10m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$153.3m−$83.5m−$53.8m−$36.0m−$20.3m−$7.1m−$6.0m−$6.1m−$4.9m−$2.9m
Capital spending−$249,000−$249,878−$97,644−$158,768−$81,898−$89,371−$380,201−$629,608−$239,848−$40,903
Free cash flow−$153.5m−$83.7m−$53.9m−$36.2m−$20.4m−$7.2m−$6.4m−$6.7m−$5.2m−$2.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue———$154,000——$121,344—
Gross profit—−$47,000—−$41,000−$40,000−$37,000−$35,254−$34,021
Operating income−$66.1m−$50.5m−$49.2m−$42.8m−$44.0m−$36.1m−$36.4m−$30.1m
Net income−$78.9m−$52.8m−$51.0m−$43.8m−$45.3m−$37.0m−$36.7m−$29.8m
Diluted earnings per share-1.44-0.96-0.97-0.83-0.86-0.70-0.85-0.69
Cash from operations−$55.0m−$55.0m−$36.0m−$44.0m−$36.0m−$35.0m−$27.0m−$20.0m
Total assets$828.2m$410.2m$466.6m$476.0m$183.6m$218.1m$245.1m$273.0m
Cash and short-term investments$182.0m$145.2m$441.5m$455.0m$168.4m$205.7m$235.1m$264.1m
Debt$257,000$323.4m$321.9m$320.3m$99.4m$98.7m$97.9m$97.1m
Shareholders' equity−$12.8m$53.5m$100.6m$117.0m$44.4m$86.7m$115.6m$149.7m

Financial ratios

Data as of 15 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin-108.4%—————
Operating margin-103827.3%—————
Net margin-114962.3%—————
Return on equity-176.1%-96.7%-45.6%-30.2%-43.1%-81.0%
Return on assets-37.9%-45.6%-33.4%-23.0%-34.5%-73.1%
Free cash flow yield-4.9%-3.2%-3.1%-3.5%-2.3%-1.1%
Earnings growth58.4%75.3%58.0%36.4%212.5%28.7%
Current ratio10.55x7.71x13.43x25.45x34.06x10.26x
Debt to equity3.20x0.85x0.27x0.26x0.22x0.02x
Equity ratio21.6%47.2%73.1%76.1%80.0%90.3%
Interest coverage-9.32x-9.87x-10.97x-18.17x-22.45x-79634.70x
R&D as a share of sales94152.6%—————
Buybacks as a share of market value-22.5%-48.4%-71.3%-13.2%-45.1%-0.3%

Growth per year

Compound annual rate

3 years5 years10 years
Operating income63.5%78.3%54.2%
Net income63.7%79.6%54.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-29.6-5.0-6.6-5.9-6.6-9.9-14.8-32.6-30.6

Market value over time

29 Sept 2017 to 14 Oct 2026, in USD

$73.4m$3.28bn

Share price return

Finished calendar years

202520242023202220212020201920182017
Return720%-17%11%6%15%8%-58%23%33%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.